Paul R. Edick

Biography

Paul R. Edick is currently President & CEO of Xeris Pharmaceuticals, a private technology based company with an initial focus on therapies for diabetes associated hypoglycemia. He was previously, (2015-2016), Founding Partner of 3G Advisors, a consultancy to the Pharmaceutical, Healthcare and Healthcare Investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (DRTX), a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Mr. Edick was CEO of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was CEO of MedPointe Healthcare, Inc., a U.S. based specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business, the development of a clinical stage portfolio, and the company was subsequently sold to Meda, AB of Sweden in 2007. Mr. Edick also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations including as: Group Vice President and President, Asia Pacific & Latin America Operations at Pharmacia; At Searle Pharmaceutical, as President of Asia Pacific, Canada & Latin America Operations, VP, Canada & Latin America Operations, and leading the U.S. managed care organization, U.S. marketing organization and the Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. Also sales, marketing, advertising and advisory positions in Procter & Gamble, Ortho Pharmaceutical and The Hamilton Group. Mr. Edick currently serves as Director of NewLink Genetics Inc. (NASDAQ: NLNK), Director of Sucampo Pharmaceuticals (NASDAQ: SCMP), Director of Neos Therapeutics (NASDAQ: NEOS), and Director of PDL BioPharma (NASDAQ: PDLI). Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards, including; as Director of Circassia Pharmaceuticals Plc (London: CIR.L), Director and Chairman of Life Cycle Pharma Ltd., (now Veloxis) (CPH: VELO), Director of Amerita Inc., and Director of Informed Medical Communications. Mr. Edick holds a BA in Psychology from Hamilton College in Clinton, NY.

Research Interest

Medical Devices